ADC Biotechnology
Sector
Scientific Technology
Deal Type
Growth Capital
Initial Investment
September 2017
Transaction size
£2.8m
Location
Deeside
Maven Office
Bristol
About ADC Bio
ADC Biotechnology (ADC Bio) is an innovative biotechnology company. It specialises in developing new process technologies for antibody drug conjugates (ADCs) which help speed up, simplify and lower the production costs of the latest generation of anticancer blockbuster ADC drugs.
ADC Bio’s proprietary Lock-Release technology is the only commercially available system that controls aggregation at source, is scaleable, ensures consistency of quality and purity, and is capable of meeting GMP regulatory requirements required to produce materials for use in human clinical trials.
The investment and development in the new facility will see the creation of a host of new, degree level and above jobs locally. We are very confident about orders and already have confirmation that many of our existing customers will use the new facility for future projects and we expect to add a number of new drug projects from companies in the USA and Europe.
Charlie Johnson, CEO at ADC Bio
Interested in growth capital for your business? Then get in touch with our investment team.
Contact us